Optimizing treatment in patients with early-stage HER2-positive breast cancer

Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses challenges in the optimization of management of early-stage HER2-positive breast cancer, including defining heterogeneity, optimal neoadjuvant and adjuvant approaches, as well as how to incorporate novel therapies into the treatment landscape such as trastuzumab deruxtecan, and tyrosine kinase inhibitors such as tucatinib. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.